HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion - Revision history

Richard.Glen: Richard.Glen moved page HAEM5:Acute myeloid leukaemia with DEK:NUP214 fusion to HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion without leaving a redirect: Link fixing

2026-10-17T19:20:30Z

Richard.Glen moved page HAEM5:Acute myeloid leukaemia with DEK:NUP214 fusion to HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion without leaving a redirect: Link fixing

← Older revision	Revision as of 14:20, 17 October 2026
(No difference)

Richard.Glen: Richard.Glen moved page HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion to HAEM5:Acute myeloid leukaemia with DEK:NUP214 fusion without leaving a redirect: Link fixing

2026-10-17T19:17:28Z

Richard.Glen moved page HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion to HAEM5:Acute myeloid leukaemia with DEK:NUP214 fusion without leaving a redirect: Link fixing

← Older revision	Revision as of 14:17, 17 October 2026
(No difference)

Bailey.Glen at 17:07, 3 July 2025

2025-07-03T17:07:05Z

← Older revision		Revision as of 12:07, 3 July 2025
Line 28:		Line 28:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	~~\|Presence of ''DEK''::''NUP214'' fusion~~
	\|-
	\|WHO Desirable Criteria (Genetics)*
	~~\|Detection of t(6;9)(p22.3;q34.1)~~
	\|-
	~~\|Other Classification~~
	~~\|N/A~~
	\|}

	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:26, 25 May 2025

2025-05-25T21:26:30Z

← Older revision		Revision as of 16:26, 25 May 2025
Line 81:		Line 81:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|N/A		\|N/A
Line 100:		Line 100:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|N/A		\|N/A
Line 119:		Line 119:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|''FLT3''		\|''FLT3''

Bailey.Glen at 20:02, 25 May 2025

2025-05-25T20:02:54Z

← Older revision		Revision as of 15:02, 25 May 2025
Line 43:		Line 43:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|Acute myeloid leukaemia with t(6;9)(p22.3;q34.1)
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|N/A
	\|}		\|}

Bailey.Glen at 19:20, 25 May 2025

2025-05-25T19:20:07Z

← Older revision		Revision as of 14:20, 25 May 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Acute myeloid leukaemia with DEK::NUP214 fusion}}		{{DISPLAYTITLE:Acute myeloid leukaemia with DEK::NUP214 fusion}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Jennelleh at 14:03, 17 May 2025

2025-05-17T14:03:18Z

← Older revision		Revision as of 09:03, 17 May 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Acute myeloid leukaemia with DEK::NUP214 fusion}}		{{DISPLAYTITLE:Acute myeloid leukaemia with DEK::NUP214 fusion}}

	N/[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

	==Primary Author(s)*==		==Primary Author(s)*==

Jennelleh at 14:01, 17 May 2025

2025-05-17T14:01:55Z

← Older revision		Revision as of 09:01, 17 May 2025
Line 153:		Line 153:
	==Genetic Diagnostic Testing Methods==		==Genetic Diagnostic Testing Methods==

	Karyotype, FISH, RT-PCR		Karyotype, FISH, RT-PCR (and any other fusion detecting technologies)

	==Familial Forms==		==Familial Forms==

Jennelleh at 14:00, 17 May 2025

2025-05-17T14:00:54Z

← Older revision		Revision as of 09:00, 17 May 2025
Line 2:		Line 2:

	N/[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		N/[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

	~~{{Under Construction}}~~

	==Primary Author(s)*==		==Primary Author(s)*==
Line 72:		Line 70:
	\|Yes (WHO)		\|Yes (WHO)
	\|		\|
	*This AML subtype is classified based on the presence of a t(6;9)(p23;q34.1), which results in fusion of the 5’ portion of ''DEK'' at “6p23” (specifically 6p22.3[hg38]) and the 3’ portion of ''NUP214''(''CAN'') at “9q34.1” (specifically 9q34.13[hg38])<ref name=":0">WHO Classification of Tumours Editorial Board, eds, WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition, IARC Press:Lyon, 2024. Online at: [https://tumourclassification.iarc.who.int/welcome/ WHO Classification of Tumours].</ref><ref>{{Cite journal\|last=Khoury\|first=Joseph D.\|last2=Solary\|first2=Eric\|last3=Abla\|first3=Oussama\|last4=Akkari\|first4=Yassmine\|last5=Alaggio\|first5=Rita\|last6=Apperley\|first6=Jane F.\|last7=Bejar\|first7=Rafael\|last8=Berti\|first8=Emilio\|last9=Busque\|first9=Lambert\|date=2022-07\|title=The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms\|url=https://pubmed.ncbi.nlm.nih.gov/35732831\|journal=Leukemia\|volume=36\|issue=7\|pages=1703–1719\|doi=10.1038/s41375-022-01613-1\|issn=1476-5551\|pmc=9252913\|pmid=35732831}}</ref>. The breakpoints are intronic, producing an in-frame fusion<ref>{{Cite journal\|last=von Lindern\|first=M.\|last2=Fornerod\|first2=M.\|last3=van Baal\|first3=S.\|last4=Jaegle\|first4=M.\|last5=de Wit\|first5=T.\|last6=Buijs\|first6=A.\|last7=Grosveld\|first7=G.\|date=1992\|title=The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA\|url=https://www.ncbi.nlm.nih.gov/pubmed/1549122\|journal=Molecular and Cellular Biology\|volume=12\|issue=4\|pages=1687–1697\|doi=10.1128/mcb.12.4.1687\|issn=0270-7306\|pmc=PMC369612\|pmid=1549122}}</ref>. The ''DEK''-''NUP214'' fusion present on the derivative chromosome 6 is considered the pathogenic entity as the reciprocal ''NUP214''-''DEK'' fusion on chromosome 9 does not appear to be transcribed<ref>{{Cite journal\|last=von Lindern\|first=M.\|last2=Fornerod\|first2=M.\|last3=Soekarman\|first3=N.\|last4=van Baal\|first4=S.\|last5=Jaegle\|first5=M.\|last6=Hagemeijer\|first6=A.\|last7=Bootsma\|first7=D.\|last8=Grosveld\|first8=G.\|date=1992\|title=Translocation t(6;9) in acute non-lymphocytic leukaemia results in the formation of a DEK-CAN fusion gene\|url=https://www.ncbi.nlm.nih.gov/pubmed/1308167\|journal=Bailliere's Clinical Haematology\|volume=5\|issue=4\|pages=857–879\|doi=10.1016/s0950-3536(11)80049-1\|issn=0950-3536\|pmid=1308167}}</ref>.		*This AML subtype is classified based on the presence of a t(6;9)(p23;q34.1), which results in fusion of the 5’ portion of ''DEK'' at “6p23” (specifically 6p22.3[hg38]) and the 3’ portion of ''NUP214''(''CAN'') at “9q34.1” (specifically 9q34.13[hg38])<ref name=":0">WHO Classification of Tumours Editorial Board, eds, WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition, IARC Press:Lyon, 2024. Online at: [https://tumourclassification.iarc.who.int/welcome/ WHO Classification of Tumours].</ref><ref>{{Cite journal\|last=Khoury\|first=Joseph D.\|last2=Solary\|first2=Eric\|last3=Abla\|first3=Oussama\|last4=Akkari\|first4=Yassmine\|last5=Alaggio\|first5=Rita\|last6=Apperley\|first6=Jane F.\|last7=Bejar\|first7=Rafael\|last8=Berti\|first8=Emilio\|last9=Busque\|first9=Lambert\|date=2022-07\|title=The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms\|url=https://pubmed.ncbi.nlm.nih.gov/35732831\|journal=Leukemia\|volume=36\|issue=7\|pages=1703–1719\|doi=10.1038/s41375-022-01613-1\|issn=1476-5551\|pmc=9252913\|pmid=35732831}}</ref>. The breakpoints are intronic, producing an in-frame fusion<ref>{{Cite journal\|last=von Lindern\|first=M.\|last2=Fornerod\|first2=M.\|last3=van Baal\|first3=S.\|last4=Jaegle\|first4=M.\|last5=de Wit\|first5=T.\|last6=Buijs\|first6=A.\|last7=Grosveld\|first7=G.\|date=1992\|title=The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA\|url=https://www.ncbi.nlm.nih.gov/pubmed/1549122\|journal=Molecular and Cellular Biology\|volume=12\|issue=4\|pages=1687–1697\|doi=10.1128/mcb.12.4.1687\|issn=0270-7306\|pmc=PMC369612\|pmid=1549122}}</ref>. The ''DEK''-''NUP214'' fusion present on the derivative chromosome 6 is considered the pathogenic entity as the reciprocal ''NUP214''-''DEK'' fusion on chromosome 9 does not appear to be transcribed<ref>{{Cite journal\|last=von Lindern\|first=M.\|last2=Fornerod\|first2=M.\|last3=Soekarman\|first3=N.\|last4=van Baal\|first4=S.\|last5=Jaegle\|first5=M.\|last6=Hagemeijer\|first6=A.\|last7=Bootsma\|first7=D.\|last8=Grosveld\|first8=G.\|date=1992\|title=Translocation t(6;9) in acute non-lymphocytic leukaemia results in the formation of a DEK-CAN fusion gene\|url=https://www.ncbi.nlm.nih.gov/pubmed/1308167\|journal=Bailliere's Clinical Haematology\|volume=5\|issue=4\|pages=857–879\|doi=10.1016/s0950-3536(11)80049-1\|issn=0950-3536\|pmid=1308167}}</ref>.
	*Typically, the ''DEK''-''NUP214'' fusion presents as the sole abnormality but can be part of a complex karyotype<ref name=":0" />.		*Typically, the ''DEK''-''NUP214'' fusion presents as the sole abnormality but can be part of a complex karyotype<ref name=":0" />.
	*Cases with the 6;9 translocation and <20% blasts are not currently classified as AML, which is controversial. Such cases should have close follow-up to monitor for development of more definitive evidence of AML or may be treated as AML if clinically appropriate<ref name=":0" />.		*Cases with the 6;9 translocation and <20% blasts are not currently classified as AML, which is controversial. Such cases should have close follow-up to monitor for development of more definitive evidence of AML or may be treated as AML if clinically appropriate<ref name=":0" />.
	*The t(6;9) occurs in 0.6-1.7% of AML cases in children<ref name=":1" /> (REFERENCES) and about 1% of adult AML cases (REFERENCES).		*The t(6;9) occurs in 0.6-1.7% of AML cases in children<ref name=":1" /> (REFERENCES) and about 1% of adult AML cases (REFERENCES).
Line 172:		Line 170:

	==References==		==References==
	~~(use the "Cite" icon at the top of the page)~~ <span style="color:#0070C0">(''Instructions: Add each reference into the text above by clicking where you want to insert the reference, selecting the “Cite” icon at the top of the wiki page, and using the “Automatic” tab option to search by PMID to select the reference to insert. If a PMID is not available, such as for a book, please use the “Cite” icon, select “Manual” and then “Basic Form”, and include the entire reference. To insert the same reference again later in the page, select the “Cite” icon and “Re-use” to find the reference; DO NOT insert the same reference twice using the “Automatic” tab as it will be treated as two separate references~~. The reference list in this section will be automatically generated and sorted''</span><span style="color:#0070C0">''.''</span><span style="color:#0070C0">)</span> <references />~~		<references />

	~~<br~~ />

	==Notes==		==Notes==

Jennelleh at 14:00, 17 May 2025

2025-05-17T14:00:07Z

← Older revision		Revision as of 09:00, 17 May 2025
Line 57:		Line 57:
	==Gene Rearrangements==		==Gene Rearrangements==
	[[File:T(6;9)(p23;q34).png]]		[[File:T(6;9)(p23;q34).png]]

	*This AML subtype is classified based on the presence of a t(6;9)(p23;q34.1), which results in fusion of the 5’ portion of ''DEK'' at “6p23” (specifically 6p22.3[hg38]) and the 3’ portion of ''NUP214''(''CAN'') at “9q34.1” (specifically 9q34.13[hg38])<ref name=":0">WHO Classification of Tumours Editorial Board, eds, WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition, IARC Press:Lyon, 2024. Online at: [https://tumourclassification.iarc.who.int/welcome/ WHO Classification of Tumours].</ref><ref>{{Cite journal\|last=Khoury\|first=Joseph D.\|last2=Solary\|first2=Eric\|last3=Abla\|first3=Oussama\|last4=Akkari\|first4=Yassmine\|last5=Alaggio\|first5=Rita\|last6=Apperley\|first6=Jane F.\|last7=Bejar\|first7=Rafael\|last8=Berti\|first8=Emilio\|last9=Busque\|first9=Lambert\|date=2022-07\|title=The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms\|url=https://pubmed.ncbi.nlm.nih.gov/35732831\|journal=Leukemia\|volume=36\|issue=7\|pages=1703–1719\|doi=10.1038/s41375-022-01613-1\|issn=1476-5551\|pmc=9252913\|pmid=35732831}}</ref>. The breakpoints are intronic, producing an in-frame fusion<ref>{{Cite journal\|last=von Lindern\|first=M.\|last2=Fornerod\|first2=M.\|last3=van Baal\|first3=S.\|last4=Jaegle\|first4=M.\|last5=de Wit\|first5=T.\|last6=Buijs\|first6=A.\|last7=Grosveld\|first7=G.\|date=1992\|title=The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA\|url=https://www.ncbi.nlm.nih.gov/pubmed/1549122\|journal=Molecular and Cellular Biology\|volume=12\|issue=4\|pages=1687–1697\|doi=10.1128/mcb.12.4.1687\|issn=0270-7306\|pmc=PMC369612\|pmid=1549122}}</ref>. The ''DEK''-''NUP214'' fusion present on the derivative chromosome 6 is considered the pathogenic entity as the reciprocal ''NUP214''-''DEK'' fusion on chromosome 9 does not appear to be transcribed<ref>{{Cite journal\|last=von Lindern\|first=M.\|last2=Fornerod\|first2=M.\|last3=Soekarman\|first3=N.\|last4=van Baal\|first4=S.\|last5=Jaegle\|first5=M.\|last6=Hagemeijer\|first6=A.\|last7=Bootsma\|first7=D.\|last8=Grosveld\|first8=G.\|date=1992\|title=Translocation t(6;9) in acute non-lymphocytic leukaemia results in the formation of a DEK-CAN fusion gene\|url=https://www.ncbi.nlm.nih.gov/pubmed/1308167\|journal=Bailliere's Clinical Haematology\|volume=5\|issue=4\|pages=857–879\|doi=10.1016/s0950-3536(11)80049-1\|issn=0950-3536\|pmid=1308167}}</ref>. Typically, the ''DEK''-''NUP214'' fusion presents as the sole abnormality but can be part of a complex karyotype<ref name=":0" />. Cases with the 6;9 translocation and <20% blasts are not currently classified as AML, which is controversial. Such cases should have close follow-up to monitor for development of more definitive evidence of AML or may be treated as AML if clinically appropriate<ref name=":0" />.

	{\| class="wikitable sortable"		{\| class="wikitable sortable"
Line 74:		Line 72:
	\|Yes (WHO)		\|Yes (WHO)
	\|		\|
			*This AML subtype is classified based on the presence of a t(6;9)(p23;q34.1), which results in fusion of the 5’ portion of ''DEK'' at “6p23” (specifically 6p22.3[hg38]) and the 3’ portion of ''NUP214''(''CAN'') at “9q34.1” (specifically 9q34.13[hg38])<ref name=":0">WHO Classification of Tumours Editorial Board, eds, WHO Classification of Tumours, Haematolymphoid Tumours, 5th edition, IARC Press:Lyon, 2024. Online at: [https://tumourclassification.iarc.who.int/welcome/ WHO Classification of Tumours].</ref><ref>{{Cite journal\|last=Khoury\|first=Joseph D.\|last2=Solary\|first2=Eric\|last3=Abla\|first3=Oussama\|last4=Akkari\|first4=Yassmine\|last5=Alaggio\|first5=Rita\|last6=Apperley\|first6=Jane F.\|last7=Bejar\|first7=Rafael\|last8=Berti\|first8=Emilio\|last9=Busque\|first9=Lambert\|date=2022-07\|title=The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms\|url=https://pubmed.ncbi.nlm.nih.gov/35732831\|journal=Leukemia\|volume=36\|issue=7\|pages=1703–1719\|doi=10.1038/s41375-022-01613-1\|issn=1476-5551\|pmc=9252913\|pmid=35732831}}</ref>. The breakpoints are intronic, producing an in-frame fusion<ref>{{Cite journal\|last=von Lindern\|first=M.\|last2=Fornerod\|first2=M.\|last3=van Baal\|first3=S.\|last4=Jaegle\|first4=M.\|last5=de Wit\|first5=T.\|last6=Buijs\|first6=A.\|last7=Grosveld\|first7=G.\|date=1992\|title=The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA\|url=https://www.ncbi.nlm.nih.gov/pubmed/1549122\|journal=Molecular and Cellular Biology\|volume=12\|issue=4\|pages=1687–1697\|doi=10.1128/mcb.12.4.1687\|issn=0270-7306\|pmc=PMC369612\|pmid=1549122}}</ref>. The ''DEK''-''NUP214'' fusion present on the derivative chromosome 6 is considered the pathogenic entity as the reciprocal ''NUP214''-''DEK'' fusion on chromosome 9 does not appear to be transcribed<ref>{{Cite journal\|last=von Lindern\|first=M.\|last2=Fornerod\|first2=M.\|last3=Soekarman\|first3=N.\|last4=van Baal\|first4=S.\|last5=Jaegle\|first5=M.\|last6=Hagemeijer\|first6=A.\|last7=Bootsma\|first7=D.\|last8=Grosveld\|first8=G.\|date=1992\|title=Translocation t(6;9) in acute non-lymphocytic leukaemia results in the formation of a DEK-CAN fusion gene\|url=https://www.ncbi.nlm.nih.gov/pubmed/1308167\|journal=Bailliere's Clinical Haematology\|volume=5\|issue=4\|pages=857–879\|doi=10.1016/s0950-3536(11)80049-1\|issn=0950-3536\|pmid=1308167}}</ref>.
			*Typically, the ''DEK''-''NUP214'' fusion presents as the sole abnormality but can be part of a complex karyotype<ref name=":0" />.
			*Cases with the 6;9 translocation and <20% blasts are not currently classified as AML, which is controversial. Such cases should have close follow-up to monitor for development of more definitive evidence of AML or may be treated as AML if clinically appropriate<ref name=":0" />.
	*The t(6;9) occurs in 0.6-1.7% of AML cases in children<ref name=":1" /> (REFERENCES) and about 1% of adult AML cases (REFERENCES).		*The t(6;9) occurs in 0.6-1.7% of AML cases in children<ref name=":1" /> (REFERENCES) and about 1% of adult AML cases (REFERENCES).
	*''DEK''::''NUP214'' has traditionally been associated with a poor prognosis in both adult and pediatric AML cases<ref name=":0" />. Of note, a 2014 retrospective analysis suggests a better outcome for pediatric patients with this translocation than previously reported<ref name=":1">{{Cite journal\|last=Sandahl\|first=Julie Damgaard\|last2=Coenen\|first2=Eva A.\|last3=Forestier\|first3=Erik\|last4=Harbott\|first4=Jochen\|last5=Johansson\|first5=Bertil\|last6=Kerndrup\|first6=Gitte\|last7=Adachi\|first7=Souichi\|last8=Auvrignon\|first8=Anne\|last9=Beverloo\|first9=H. Berna\|date=2014\|title=t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients\|url=https://www.ncbi.nlm.nih.gov/pubmed/24441146\|journal=Haematologica\|volume=99\|issue=5\|pages=865–872\|doi=10.3324/haematol.2013.098517\|issn=1592-8721\|pmc=4008104\|pmid=24441146}}</ref>. Elevated white blood cell counts and higher bone marrow blast percentages are associated with shorter periods of overall survival and disease-free survival, respectively<ref name=":0" />. Limited data suggests early allogeneic stem cell transplantation may be associated with better overall survival compared to patients without transplantation, suggesting accurate diagnosis for these patients is crucial<ref name=":0" /><ref>{{Cite journal\|last=Slovak\|first=M. L.\|last2=Gundacker\|first2=H.\|last3=Bloomfield\|first3=C. D.\|last4=Dewald\|first4=G.\|last5=Appelbaum\|first5=F. R.\|last6=Larson\|first6=R. A.\|last7=Tallman\|first7=M. S.\|last8=Bennett\|first8=J. M.\|last9=Stirewalt\|first9=D. L.\|date=2006\|title=A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies\|url=https://www.ncbi.nlm.nih.gov/pubmed/16628187\|journal=Leukemia\|volume=20\|issue=7\|pages=1295–1297\|doi=10.1038/sj.leu.2404233\|issn=0887-6924\|pmid=16628187}}</ref><ref>{{Cite journal\|last=Ishiyama\|first=K.\|last2=Takami\|first2=A.\|last3=Kanda\|first3=Y.\|last4=Nakao\|first4=S.\|last5=Hidaka\|first5=M.\|last6=Maeda\|first6=T.\|last7=Naoe\|first7=T.\|last8=Taniguchi\|first8=S.\|last9=Kawa\|first9=K.\|date=2012\|title=Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis\|url=https://www.ncbi.nlm.nih.gov/pubmed/21869835\|journal=Leukemia\|volume=26\|issue=3\|pages=461–464\|doi=10.1038/leu.2011.229\|issn=1476-5551\|pmid=21869835}}</ref>.		*''DEK''::''NUP214'' has traditionally been associated with a poor prognosis in both adult and pediatric AML cases<ref name=":0" />. Of note, a 2014 retrospective analysis suggests a better outcome for pediatric patients with this translocation than previously reported<ref name=":1">{{Cite journal\|last=Sandahl\|first=Julie Damgaard\|last2=Coenen\|first2=Eva A.\|last3=Forestier\|first3=Erik\|last4=Harbott\|first4=Jochen\|last5=Johansson\|first5=Bertil\|last6=Kerndrup\|first6=Gitte\|last7=Adachi\|first7=Souichi\|last8=Auvrignon\|first8=Anne\|last9=Beverloo\|first9=H. Berna\|date=2014\|title=t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients\|url=https://www.ncbi.nlm.nih.gov/pubmed/24441146\|journal=Haematologica\|volume=99\|issue=5\|pages=865–872\|doi=10.3324/haematol.2013.098517\|issn=1592-8721\|pmc=4008104\|pmid=24441146}}</ref>. Elevated white blood cell counts and higher bone marrow blast percentages are associated with shorter periods of overall survival and disease-free survival, respectively<ref name=":0" />. Limited data suggests early allogeneic stem cell transplantation may be associated with better overall survival compared to patients without transplantation, suggesting accurate diagnosis for these patients is crucial<ref name=":0" /><ref>{{Cite journal\|last=Slovak\|first=M. L.\|last2=Gundacker\|first2=H.\|last3=Bloomfield\|first3=C. D.\|last4=Dewald\|first4=G.\|last5=Appelbaum\|first5=F. R.\|last6=Larson\|first6=R. A.\|last7=Tallman\|first7=M. S.\|last8=Bennett\|first8=J. M.\|last9=Stirewalt\|first9=D. L.\|date=2006\|title=A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies\|url=https://www.ncbi.nlm.nih.gov/pubmed/16628187\|journal=Leukemia\|volume=20\|issue=7\|pages=1295–1297\|doi=10.1038/sj.leu.2404233\|issn=0887-6924\|pmid=16628187}}</ref><ref>{{Cite journal\|last=Ishiyama\|first=K.\|last2=Takami\|first2=A.\|last3=Kanda\|first3=Y.\|last4=Nakao\|first4=S.\|last5=Hidaka\|first5=M.\|last6=Maeda\|first6=T.\|last7=Naoe\|first7=T.\|last8=Taniguchi\|first8=S.\|last9=Kawa\|first9=K.\|date=2012\|title=Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis\|url=https://www.ncbi.nlm.nih.gov/pubmed/21869835\|journal=Leukemia\|volume=26\|issue=3\|pages=461–464\|doi=10.1038/leu.2011.229\|issn=1476-5551\|pmid=21869835}}</ref>.